Rituximab biosimilar - Harvest Moon Pharmaceuticals

Drug Profile

Rituximab biosimilar - Harvest Moon Pharmaceuticals

Latest Information Update: 03 Jul 2015

Price : $50

At a glance

  • Originator Harvest Moon Pharmaceuticals
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Immunological disorders

Most Recent Events

  • 03 Jul 2015 Research is ongoing in USA
  • 17 Jun 2015 Rituximab biosimilar - Harvest Moon Pharmaceuticals is available for licensing as of 17 Jun 2015. www.harvestmoonpharma.com
  • 09 Jun 2015 Biosimilars no longer licensed to PanPharmaceuticals USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top